RS64288B1 - Kompozicije agonisti gip/glp1 - Google Patents

Kompozicije agonisti gip/glp1

Info

Publication number
RS64288B1
RS64288B1 RS20230480A RSP20230480A RS64288B1 RS 64288 B1 RS64288 B1 RS 64288B1 RS 20230480 A RS20230480 A RS 20230480A RS P20230480 A RSP20230480 A RS P20230480A RS 64288 B1 RS64288 B1 RS 64288B1
Authority
RS
Serbia
Prior art keywords
gip
agonist compositions
glp1 agonist
glp1
compositions
Prior art date
Application number
RS20230480A
Other languages
English (en)
Inventor
Vincent John Corvari
Christopher Sears Minie
Dinesh Shyandeo Mishra
Ken Kangyi Qian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67263049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64288(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS64288B1 publication Critical patent/RS64288B1/sr
Publication of RS64288B9 publication Critical patent/RS64288B9/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
RS20230480A 2018-06-22 2019-06-14 Kompozicije agonisti gip/glp1 RS64288B9 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688632P 2018-06-22 2018-06-22
EP19739766.4A EP3810201B9 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions
PCT/US2019/037146 WO2019245893A2 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions

Publications (2)

Publication Number Publication Date
RS64288B1 true RS64288B1 (sr) 2023-07-31
RS64288B9 RS64288B9 (sr) 2023-11-30

Family

ID=67263049

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230480A RS64288B9 (sr) 2018-06-22 2019-06-14 Kompozicije agonisti gip/glp1

Country Status (33)

Country Link
US (3) US11357820B2 (sr)
EP (2) EP4257185A3 (sr)
JP (3) JP6896945B2 (sr)
KR (3) KR20240060873A (sr)
CN (1) CN112312926A (sr)
AR (1) AR115542A1 (sr)
AU (2) AU2019289110B2 (sr)
BR (1) BR112020023452A2 (sr)
CA (1) CA3103469C (sr)
CL (1) CL2020003359A1 (sr)
CR (1) CR20200634A (sr)
DK (1) DK3810201T5 (sr)
EA (1) EA202092713A1 (sr)
EC (1) ECSP20082717A (sr)
ES (1) ES2953740T3 (sr)
FI (1) FI3810201T3 (sr)
HR (1) HRP20230748T1 (sr)
HU (1) HUE063059T2 (sr)
IL (2) IL295433B2 (sr)
JO (1) JOP20200335A1 (sr)
LT (1) LT3810201T (sr)
MA (1) MA52965B1 (sr)
MD (1) MD3810201T2 (sr)
MX (1) MX2020013727A (sr)
PE (1) PE20210049A1 (sr)
PH (1) PH12020552215A1 (sr)
PL (1) PL3810201T3 (sr)
PT (1) PT3810201T (sr)
RS (1) RS64288B9 (sr)
SG (1) SG11202012744UA (sr)
SI (1) SI3810201T1 (sr)
TW (1) TWI705820B (sr)
WO (1) WO2019245893A2 (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
JP2021533094A (ja) * 2018-07-23 2021-12-02 イーライ リリー アンド カンパニー 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法
EP3883635A1 (en) * 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CN117866049A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
WO2024006662A1 (en) * 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
TW202412835A (zh) * 2022-09-23 2024-04-01 大陸商博瑞生物醫藥(蘇州)股份有限公司 一種glp-1和gip雙受體激動劑藥物組合物及其用途
WO2024086601A2 (en) * 2022-10-19 2024-04-25 Eli Lilly And Company Preserved gip/glp agonist compositions
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
AU3473999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Injectable igf-formulations containing succinate as buffering agent
EP1695983B1 (en) 2000-06-16 2009-03-04 Eli Lilly & Company Glucagon-like peptide-1 analogs
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102784386A (zh) * 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
ES2575984T3 (es) 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
AU2005319432A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company GLP-1 analog fusion protein formulations
CA2614754A1 (en) * 2005-07-12 2007-01-18 Renovo Ltd Pharmaceutical compositions comprising a tgf-beta superfamily member
CN101453988A (zh) * 2006-04-14 2009-06-10 曼金德公司 高血糖素样肽1（glp-1）药物制剂
WO2008019147A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
AU2008275180A1 (en) 2007-07-10 2009-01-15 Eli Lilly And Company GLP-1-Fc fusion protein formulation
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
DK2708252T3 (en) 2010-03-01 2015-11-02 Lilly Co Eli Automatic injection device with delay mechanism including double acting biasing element
DK2723367T3 (en) 2011-06-22 2017-07-17 Univ Indiana Res & Tech Corp Glucagon / GLP-1 receptor-CO-AGONISTS
SG11201407137PA (en) 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
BR112014032938A2 (pt) 2012-07-01 2017-08-01 Novo Nordisk As uso de peptídeos de glp-1 de longa ação
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
CN105324126A (zh) 2013-06-21 2016-02-10 诺和诺德股份有限公司 Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
MX2018014016A (es) * 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
MA52965B1 (fr) 2023-08-31
JOP20200335A1 (ar) 2020-12-20
US11918623B2 (en) 2024-03-05
EP3810201B9 (en) 2023-08-02
SG11202012744UA (en) 2021-01-28
MX2020013727A (es) 2021-03-02
EA202092713A1 (ru) 2021-04-05
KR20210010572A (ko) 2021-01-27
CL2020003359A1 (es) 2021-06-25
CR20200634A (es) 2021-01-21
TW202015717A (zh) 2020-05-01
IL295433B2 (en) 2024-03-01
US20240226229A1 (en) 2024-07-11
SI3810201T1 (sl) 2023-08-31
AU2022279524A1 (en) 2023-02-02
WO2019245893A3 (en) 2020-03-12
PH12020552215A1 (en) 2021-06-28
CA3103469A1 (en) 2019-12-26
JP2024041808A (ja) 2024-03-27
MA52965A (fr) 2021-04-28
TWI705820B (zh) 2020-10-01
CN112312926A (zh) 2021-02-02
RS64288B9 (sr) 2023-11-30
EP4257185A3 (en) 2024-01-17
ECSP20082717A (es) 2021-01-29
JP7413315B2 (ja) 2024-01-15
US20190388502A1 (en) 2019-12-26
AU2019289110B2 (en) 2022-10-06
ES2953740T3 (es) 2023-11-15
WO2019245893A2 (en) 2019-12-26
KR102523489B1 (ko) 2023-04-21
CA3103469C (en) 2024-04-09
EP4257185A2 (en) 2023-10-11
KR20240060873A (ko) 2024-05-08
EP3810201B1 (en) 2023-06-07
KR20230058172A (ko) 2023-05-02
IL295433B1 (en) 2023-11-01
DK3810201T5 (da) 2023-08-21
PL3810201T3 (pl) 2023-09-25
DK3810201T3 (da) 2023-06-26
HRP20230748T1 (hr) 2023-10-27
PE20210049A1 (es) 2021-01-08
BR112020023452A2 (pt) 2021-02-23
IL279504B (en) 2022-09-01
LT3810201T (lt) 2023-07-25
MD3810201T2 (ro) 2023-11-30
PT3810201T (pt) 2023-07-04
AU2019289110A1 (en) 2021-01-21
JP2021506952A (ja) 2021-02-22
US11357820B2 (en) 2022-06-14
JP6896945B2 (ja) 2021-06-30
IL295433A (en) 2022-10-01
FI3810201T3 (fi) 2023-08-17
EP3810201A2 (en) 2021-04-28
IL279504A (en) 2021-01-31
US20220273762A1 (en) 2022-09-01
JP2021167314A (ja) 2021-10-21
HUE063059T2 (hu) 2023-12-28
AR115542A1 (es) 2021-01-27

Similar Documents

Publication Publication Date Title
IL279504A (en) GIP/GLP1 agonist compounds
IL279827A (en) GIP/GLP1 co-agonist compounds
GB201810492D0 (en) Composition
GB201911800D0 (en) Antiflouling Composition
GB201820878D0 (en) Composition
GB201811100D0 (en) Composition
GB2606975B (en) Composition
GB201804434D0 (en) Composition
GB2583657B (en) Composition
GB201909924D0 (en) Composition
GB201901161D0 (en) Composition
GB201818827D0 (en) Composition
GB201819861D0 (en) Composition
GB201815032D0 (en) Composition
GB201810024D0 (en) Composition
GB201809123D0 (en) Composition
GB201801596D0 (en) Composition
GB201913398D0 (en) Composition
GB201820082D0 (en) Composition
GB201818567D0 (en) Composition
GB201815704D0 (en) Composition
GB201815420D0 (en) Composition
GB201813442D0 (en) Composition
GB201811889D0 (en) Composition
GB201811149D0 (en) Composition